SEC Tracker
Get the app

Annovis Bio ANVS

Annovis Bio Q1 FY24: revenue $0; diluted EPS −$0.72

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Annovis Bio reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$1.1MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.72No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$3.1MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$7.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Annovis Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  2. Karyopharm Therapeutics KPTI public float $37M, Jun 30, 2025
  3. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  4. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
  5. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025